• 1
    Pang KS, Rodrigues AD, Peter RM. Enzyme- and Transporter-Based Drug–Drug Interaction, 1st edn. New York: Springer, 2010.
  • 2
    Abarca J, Malone D, Armstrong E, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 2004; 44: 13641.
  • 3
    Fulda TR, Valuck RJ, Vander Zanden J, Parker S, Byrns PJ. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res 2000; 61: 54048.
  • 4
    Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007; 63: 70914.
  • 5
    Chao S, Maibach H. Lack of drug interaction conformity in commonly used drug-interaction compendia for selected at-risk dermatological drugs. Am J Clin Dermatol 2005; 6: 10511.
  • 6
    Vasudev A, Harrison R. Prescribing safely in elderly psychiatric wards: survey of possible drug interactions. Psychiatr Bull 2008; 32: 4178.
  • 7
    Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 18591.
  • 8
    Weingart SA, Toth M, Sands DZ, Aronson MD, Davis RB, Phillips RS. Physician's decisions to override computarized drug alerts in primary care. Arch Intern Med 2003; 163: 262531.
  • 9
    Isaac T, Weissman JS, Davis RB, Massagli M, Cyrulik A, Sands DZ, Weingart SN. Overrides of medication alerts in ambulatory care. Arch Intern Med 2009; 169: 30911.
  • 10
    Taylor LK, Tamblyn R. Reasons for physician non-adherence to electronic drug alerts. Stud Health Technol Inform 2004; 107: 110105.
  • 11
    Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006; 316: 33648.
  • 12
    Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan LS, Grimm SW, Kao J, King SP, Miwa G, Ni L, Kumar GN, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 81532.
  • 13
    US Food and Drug Administration. Guidance for Industry Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling. Draft Guidance. Rockville, MD: US Food and Drug Administration, 2006.
  • 14
    Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine, 2007. Available at (last accessed 31 January 2010).
  • 15
    Li X, He Y, Ruiz CH, Koenig M, Cameron MD. Characterization of dasatanib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos 2009; 37: 124250.
  • 16
    Li X, Kamenecka TM, Cameron MD. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 2010; 38: 123745.
  • 17
    Polasek TM, Miners JO. In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 2007; 3: 32129.
  • 18
    Venkatakrishnan K, Obach RS. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 2007; 8: 44962.
  • 19
    MIMS. Emims Version 5.01.0097. Sydney: CMPMedica Australia Pty Ltd, 2010.
  • 20
    Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 2010; 38: 98187.
  • 21
    Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH. Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. Curr Drug Metab 2007; 8: 8104.
  • 22
    Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997; 62: 34854.
  • 23
    Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen PJ. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298305.
  • 24
    Foti RS, Wahlstrom JL. CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos 2008; 36: 52328.
  • 25
    Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 2006; 34: 196675.
  • 26
    Miners JO, Wing LMH, Lillywhite KJ, Robson RA. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. Br J Clin Pharmacol 1985; 20: 21923.
  • 27
    Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan V. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 2006; 62: 29196.
  • 28
    Nolan PE, Erstad BL, Hoyer GL, Bliss M, Gear K, Marcus FI. Steady-state interaction between amiodarone and phenytoin in normal subjects. Am J Cardiol 1990; 65: 125257.
  • 29
    O'Reilly RA, Trager WF, Rettie AE, Goulart DA. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 1987; 42: 29094.
  • 30
    Szewczuk-Boguslawska M, Kiejna A, Beszlej JA, Orzechowska-Juzwenko K, Milejski P. Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol 2004; 56: 49194.
  • 31
    Gram LF, Brosen K. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 1993; 35: 64952.
  • 32
    Härtter S, Dingemanse J, Baier D, Ziegler G, Hiemke C. Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacology 1998; 135: 226.
  • 33
    Polasek TM, Miners JO. Macrolide-theophylline interactions: no role for the inhibition of cytochrome P4501A2. Br J Clin Pharmacol 2008; 66: 898900.
  • 34
    Birkett DJ, Miners JO. Methylxanthines. In: Metabolic Drug Interactions, 1st edn, eds Levy RH, Thummel K, Trager WF, Hansten PD, Eichelbaum M. Philidelphia, PA: Lippincott Williams & Wilkins, 2000; 46982.